Could heart cells help muscles? new trial for duchenne MD
NCT ID NCT05126758
First seen Jan 07, 2026 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This phase 3 trial tests a cell therapy called deramiocel (CAP-1002) in 106 boys and young men with Duchenne muscular dystrophy. Participants receive either the cells or a placebo every 3 months for a year, then all can get the cells for another year. The goal is to see if the treatment improves arm and hand function and protects the heart.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENETIC DISEASES, INBORN are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Akron Children's Hospital
Akron, Ohio, 44308, United States
-
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611, United States
-
Arkansas Children's Hospital
Little Rock, Arkansas, 72202, United States
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Children's Health Specialty Care Pavilion
Dallas, Texas, 75207, United States
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital of Los Angeles, Division of Neurology
Los Angeles, California, 90027, United States
-
Children's Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Phoenix Children's Hospital
Phoenix, Arizona, 85016, United States
-
Rare Disease Research NC LLC
Hillsborough, North Carolina, 27278, United States
-
Rare Disease Research, LLC
Atlanta, Georgia, 30329, United States
-
Saint Louis Children's Hospital
St Louis, Missouri, 63110, United States
-
Seattle Children's
Seattle, Washington, 98105, United States
-
UCSD Altman Clinical and Translational Research Institute
La Jolla, California, 92037, United States
-
University of California, Davis
Sacramento, California, 95817, United States
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
-
University of Missouri Health Care
Columbia, Missouri, 65212, United States
-
University of Utah Hospital
Salt Lake City, Utah, 84112, United States
-
University of Virginia Children's Hospital
Charlottesville, Virginia, 22903, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
deramiocel (CAP-1002), a type of heart-derived cell
What this could lead to
If it works, this could slow the loss of arm and hand function and help preserve heart muscle in boys and young men with Duchenne muscular dystrophy.
What could go wrong
This is an early-stage phase 3 trial with only 106 participants, so results may not apply to everyone. The treatment requires repeated infusions and may not improve function for all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.